Marčec, R., Dodig, V. M. & Likić, R. (2023). Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?. Journal of Infection, 86. (1), 66-117. doi: 10.1016/j.jinf.2022.10.030
Marčec, Robert, et al. "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?." Journal of Infection, vol. 86, no. 1, 2023, pp. 66-117. https://doi.org/10.1016/j.jinf.2022.10.030
Marčec, Robert, Vinko Michael Dodig and Robert Likić. "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?." Journal of Infection 86, no. 1 (2023): 66-117. https://doi.org/10.1016/j.jinf.2022.10.030
Marčec, R., Dodig, V. M. and Likić, R. (2023) 'Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?', Journal of Infection, 86(1), pp. 66-117. doi: 10.1016/j.jinf.2022.10.030
Marčec R, Dodig VM, Likić R. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?. Journal of Infection [Internet]. 2023 January [cited 2024 November 07];86(1):66-117. doi: 10.1016/j.jinf.2022.10.030
R. Marčec, V. M. Dodig and R. Likić, "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?", Journal of Infection, vol. 86, no. 1, pp. 66-117, January 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:888007. [Accessed: 07 November 2024]
